anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute noise-induced loss of synapses between inner hair cells (IHCs) and auditory nerve fibers (ANFs) has been documented in several strains of mice, but the extent of post-exposure recovery reportedly varies dramatically. If such inter-strain heterogeneity is real, it could be exploited to probe molecular pathways mediating neural remodeling in the adult cochlea. Here, we compared synaptopathy repair in CBA/CaJ vs. C57BL/6J, which are at opposite ends of the reported recovery spectrum. We evaluated C57BL/6J mice 0 h, 24 h, 2 wks or 8 wks after exposure for 2 h to octave-band noise (8-16 kHz) at either 90, 94 or 98 dB SPL, to compare with analogous post-exposure results in CBA/CaJ at 98 or 101 dB. We counted pre- and post-synaptic puncta in immunostained cochleas, using machine learning to classify paired (GluA2 and CtBP2) vs. orphan (CtBP2 only) puncta, and batch-processing to quantify immunostaining intensity. At 98 dB, both strains show ongoing loss of ribbons and synapses between 0 and 24 h, followed by partial recovery, however the extent and degree of these changes were greater in C57BL/6J. Much of the synaptic recovery is due to transient reduction in GluA2 intensity in synaptopathic regions. In contrast, CtBP2 intensity showed only transient increases (at 2 wks). Neurofilament staining revealed transient extension of ANF terminals in C57BL/6J, but not in CBA/CaJ, peaking at 24 h and reverting by 2 wks. Thus, although interstrain differences in synapse recovery are dominated by reversible changes in GluA2 receptor levels, the neurite extension seen in C57BL/6J suggests a qualitative difference in regenerative capacity.
FIELD: oncological urology. SUBSTANCE: invention is projected for use in preoperative period when treating locally spread and secondary forms of urinary bladder cancer. Two 100 ml portions of blood are proposed to be successively taken from each patient and stored in two sterile bottle with glugicyre. Into the first bottle are then added 50-60 ru/sq.m of doxorubicin and 60-800 mg/sq.m of cyclophosphane. Into the second bottle are added 80-100 mg/sq. m of cis-platinum. After exposition in thermostat at 36.5-37.7 C for 30 min, autoblood with cytostatics is reinfused: first, from the first bottle, then hydration with 1000 ml of glucose is performed to reduce nephrotoxicity, then autoblood from the second bottle is infused, and, finely, hemodese solution with 2 ml of lasix is injected. Preparations are infused once a week and total number of infusions is 2-3. EFFECT: enhanced treatment efficiency. 5 dwg, 1 tbl, 2 ex
This 4-year, multisite trial (Houston, New Orleans and San Antonio) will use a pragmatic randomized trial design to examine the effectiveness and implementation potential of a brief cognitive behavioral therapy(bCBT) intervention for anxiety delivered either in-person or via VA Video Connect-Home (VVC-H), according to patient preference. Brief CBT will be delivered by existing Primary Care Mental Health Integration (PCMHI) providers at three large VAMCs (Houston, New Orleans, and San Antonio). Aim 1 will examine the clinical effectiveness of the bCBT intervention vs. Enhanced Usual Care (EUC) for anxiety at 4-, 8-, and 12-month follow-ups. Aim 2 will determine factors associated with bCBT response and explore Veteran demographic and clinical factors associated with VVC-H engagement. An exploratory aim will use mixed, qualitative and quantitative methods to better understand implementation successes and challenges related to delivery and impact of bCBT anxiety and VVC-H use in the PCMHI setting. The primary hypothesis is that anxiety outcomes, as measured by the General Anxiety Disorder 7-item scale (GAD-7) will be superior at 4-, 8-, and 12-month follow up for patients who are assigned to receive bCBT vs. EUC.

In addition, participants will be asked to complete the Diversity Supplement measures and qualitative interview to evaluate whether sociocultural factors are associated with the severity and type of anxiety symptoms among Veterans of different race/ethnicity groups.
BACKGROUND: To date hysteroscopy is the gold standard technique for the evaluation and management of intrauterine pathologies. The cervical canal represents the access route to the uterine cavity. The presence of cervical stenosis often makes entry into the uterine cavity difficult and occasionally impossible. Cervical stenosis has a multifactorial etiology. It is the result of adhesion processes that can lead to the narrowing or total obliteration of the cervical canal.
PURPOSE: In this review, we summarize the scientific evidence about cervical stenosis, aiming to identify the best strategy to overcome this challenging condition.
METHODS: The literature review followed the scale for the quality assessment of narrative review articles (SANRA). All articles describing the hysteroscopic management of cervical stenosis were considered eligible. Only original papers that reported data on the topic were included.
RESULTS: Various strategies have been proposed to address cervical stenosis, including surgical and non-surgical methods. Medical treatments such as the preprocedural use of cervical-ripening agents or osmotic dilators have been explored. Surgical options include the use of cervical dilators and hysteroscopic treatments.
CONCLUSIONS: Cervical stenosis can present challenges in achieving successful intrauterine procedures. Operative hysteroscopy has been shown to have the highest success rate, particularly in cases of severe cervical stenosis, and is currently considered the gold standard for managing this condition. Despite the availability of miniaturized instruments that have made the management of cervical stenosis more feasible, it remains a complex task, even for experienced hysteroscopists.
Patients treated with ropinirole have reported falling asleep while engaged in activities of daily living, including driving or operating machinery, which sometimes resulted in accidents. Although many of these patients reported somnolence while on ropinirole, some perceived that they had no warning signs, such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some have reported these events more than 1 year after initiation of treatment.

In controlled clinical trials, somnolence was commonly reported in patients receiving ropinirole and was more frequent in Parkinson’s disease (up to 40% ropinirole, 6% placebo) than in Restless Legs Syndrome (12% ropinirole, 6% placebo) [see Adverse Reactions (6.1)].

It has been reported that falling asleep while engaged in activities of daily living usually occurs in a setting of pre-existing somnolence, although patients may not give such a history. For this reason, prescribers should reassess patients for drowsiness or sleepiness, especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.

Before initiating treatment with ropinirole tablets, patients should be advised of the potential to develop drowsiness and specifically asked about factors that may increase the risk with ropinirole such as concomitant sedating medications or alcohol, the presence of sleep disorders (other than RLS), and concomitant medications that increase ropinirole plasma levels (e.g., ciprofloxacin) [see Drug Interactions (7.1)]. If a patient develops significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., driving a motor vehicle, conversations, eating), ropinirole tablets should ordinarily be discontinued [see Dosage and Administration (2.2, 2.3)]. If a decision is made to continue ropinirole tablets, patients should be advised to not drive and to avoid other potentially dangerous activities. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.
Treatment of signs of aging of the skin and dry skin involves administration of a composition containing at least one lignan derivative or its plant extract in a medium. Treatment of signs of aging of the skin and dry skin involves administration of a composition containing at least one lignan derivative of formula (I) (0.001 - 10, preferably 0.01 - 2%) or its plant extract in a medium. [Image] R1, R2-CH2OH; R1+R2a furanone ring; R3 and R4a hydroxyl group or -OCH3; R5 - R7R3 or H; R8 and R9H; and R8+R9bond. Provided that at least one of R3 and R4, and at least one of R5 - R7 is -OCH3. An independent claim is included for a composition comprising (I) or its plant extract and at least one compound selected from desquamating agent; moisturizer; depigmenting or propigmenting agent; antiglycation agent; NO-synthase inhibitor; agent for stimulating the synthesis of dermal or epidermal macromolecule and/or for preventing their degradation; agent for stimulating the proliferation of fibroblast and/or keratinocyte or for stimulating the differentiation of keratinocyte; muscle relaxant; tensioning agent; antipollution agent and/or free-radical scavenger; agent acting on the capillary circulation; and/or agent acting on the energy metabolism of cells. ACTIVITY : Dermatological. Effect of secoisolariciresinol (A) on human dermal fibroblasts was tested. The fibroblasts were inoculated into 96-well plates for 80% confluence and were cultured in DMEM medium with 10% fetal calf serum. After a preincubation period, the cells were placed in contact with (A) (30 MicroM) for 48 hours. A radioactive precursor, L-(2,3-3H)proline was then introduced into the culture medium (16.6 MicroCi/ml). The labeling time was 24 hours. The synthesized collagen was then extracted by adding chaotropic buffer. The proteins were precipitated and the precipitates were washed and counted. The results showed % control for (A)/control was 124/100. MECHANISM OF ACTION : None given.
Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
A first pharmacologically active substance contained in a pharmaceutical, which acts on a specific biological function, is released according to a predetermined release profile (D. 1 ), FIG.  1,  and generates a first activity profile ( 1.1 ) that has flank phases with increasing and decreasing activity intensity. For changing such flank phases, an additional pharmacologically active substance is used which acts on the same biological function and which is released according to a release profile (D. 2 ) such that its activity profile (I .2 ) overlays the first activity profile (I .1 ) within the flank phase to be changed. For shortening an end flank phase, an additional substance is used whose activity is counter to the activity of the first substance and cancels, reduces, or overpowers this activity in its declining phase. Accordingly, with the aforementioned pharmaceutical, undesirable aftereffects of a pharmacologically active substance, for example, can be prevented. In one embodiment, a sedative is contained as a first pharmacologically active substance, which is released immediately, and a stimulant, which is released with delay and thus counteracts uncomfortable aftereffects of the sedative in its end phase, is contained as an additional pharmacologically active substance.
Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
Reinforcement interventions have pronounced effects on reducing cocaine use. We developed and evaluated a low-cost reinforcement intervention, systematically moving it through the Stages of development to dissemination and broad clinical implementation. In an ongoing project, reinforcement interventions are yielding benefits when reinforcers are provided at treatment initiation and for longer durations. However, less than half of patients remain engaged for 12 weeks with traditional reinforcement interventions, which require frequent attendance for monitoring and reinforcing abstinence. Interventions that extend into aftercare and that are acceptable to and efficacious in preventing long-term relapse are critically needed.

Reinforcement interventions are efficacious during periods they are in effect, and pilot data show that variable interval (VI) reinforcement schedules, once behavior change occurs, hold potential for maintaining gains when administered infrequently. Assessing methods to extend benefits of these interventions is of paramount scientific and clinical concern. This study will evaluate a novel approach in which reinforcement frequency varies by patient performance. In this intervention, reinforcement will be available for 24 weeks, on a progressive VI schedule, that adapts according to patient status. Patients who maintain abstinence earn maximum reinforcers as infrequently as every three weeks on average, while frequency of monitoring and reinforcing abstinence will increase in those who relapse until abstinence is re-instated.

To test efficacy, 280 patients with cocaine use disorder will be randomly assigned to: standard care (SC), SC+traditional twice weekly reinforcement, or SC+adaptive VI reinforcement. Evaluations will be completed at baseline and throughout 18 months to assess objective and self-reported indices of drug use, psychosocial problems, and HIV risk behaviors. Primary hypotheses are (1) the adaptive VI reinforcement intervention will improve outcomes relative to standard care during the treatment period and throughout follow-up, and (2) the adaptive VI reinforcement intervention will improve outcomes relative to the traditional reinforcement system. This study will also evaluate the roles of cognitive control and treatment outcome. Patients with better cognitive control are expected to maintain longer durations of abstinence across conditions. If these measures differentially relate to outcomes across treatments, such results suggest the potential of pairing reinforcement interventions to individuals most likely to benefit from them; they may also indicate possible markers of response in a treatment-specific manner. If cognitive indices mediate treatment response, future studies can refine interventions to improve cognitive processes and long-term outcomes.
UNLABELLED: Clear cell renal cell carcinoma (ccRCC) incidence has risen steadily over the last decade. Elevated lipid uptake and storage is required for ccRCC cell viability. As stored cholesterol is the most abundant component in ccRCC intracellular lipid droplets, it may also play an important role in ccRCC cellular homeostasis. In support of this hypothesis, ccRCC cells acquire exogenous cholesterol through the high-density lipoprotein receptor SCARB1, inhibition or suppression of which induces apoptosis. Here, we showed that elevated expression of 3 beta-hydroxy steroid dehydrogenase type 7 (HSD3B7), which metabolizes cholesterol-derived oxysterols in the bile acid biosynthetic pathway, is also essential for ccRCC cell survival. Development of an HSD3B7 enzymatic assay and screening for small-molecule inhibitors uncovered the compound celastrol as a potent HSD3B7 inhibitor with low micromolar activity. Repressing HSD3B7 expression genetically or treating ccRCC cells with celastrol resulted in toxic oxysterol accumulation, impaired proliferation, and increased apoptosis in vitro and in vivo. These data demonstrate that bile acid synthesis regulates cholesterol homeostasis in ccRCC and identifies HSD3B7 as a plausible therapeutic target.
SIGNIFICANCE: The bile acid biosynthetic enzyme HSD3B7 is essential for ccRCC cell survival and can be targeted to induce accumulation of cholesterol-derived oxysterols and apoptotic cell death.
A written informed consent will be taken from the patients.The study involved adults of either sexes (age 18-65 years) of ASA I-II who will be listed for elective functional endoscopic sinus surgery (FESS) under general anesthesia, with normal accepted coagulation profile and hematocrit value ≥30 %. Excluded from the study patients with chronic renal failure, liver cirrhosis, bleeding disorders, current anticoagulant therapy, pregnancy or breastfeeding, impaired color vision, severe vascular ischemia, history of venous thrombosis, pulmonary embolism, long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery, a hemoglobin (HB) concentration \<10 mg/dl or allergy to TXA.

Randomization: A random number sequence created by an internet website (http://www. random.org) will be used for patients' allocation. The random number sequence was retained in closed opaque envelopes released the day of the surgery by an independent physician not involved in the study. Patients will be assigned randomly to three groups (30 subjects each); saline placebo (Group S) and two different doses of preemptive nebulized tranexamic acid (Group T1) and (Group T2).To keep blinding, Group S will receive 2 sessions of nebulization each by 5 ml saline. Group T1 will receive one nebulization session 500 mg tranexamic acid (5 ml) and another one by 5 ml saline. Group T2 will receive 2 nebulization sessions each by 500 mg tranexamic acid (each by 5 ml)
BACKGROUND: While previous reports have shown that hepatitis B virus (HBV) infection affects lipid metabolism and vice versa, the impact of dyslipidemia on the functional cure of HBV infection following peginterferon alfa (PegIFNα) therapy remains unknown. Hence, this study aimed to investigate the effect of dyslipidemia on hepatitis B surface antigen (HBsAg) clearance and develop a nomogram model for predicting patients for whom PegIFNα therapy is indicated.
METHODS: A total of 160 nucleos(t)ide analogues (NAs)- experienced chronic hepatitis B (CHB) patients treated with PegIFNα (180 µg/week) were enrolled in this study. The relationship between serum lipid and HBsAg clearance was analysed. Univariate and multivariate COX analyses were used to construct and plot the nomogram model. The area under the receiver operating characteristic curve (AUC) and calibration curve were used to evaluate the discrimination and calibration of the model, respectively.
RESULTS: After 48 weeks of PegIFNα therapy, a total of 33 patients in the cohort achieved HBsAg clearance. Univariate and multivariate COX analyses indicated that dyslipidemia was significantly associated with HBsAg clearance and was an independent predictor of HBsAg clearance (HR = 0.243, P = 0.001). Kaplan-Meier survival analyses show that cumulative HBsAg clearance was significantly higher in the normolipidemic group than in the dyslipidemia group (log-rank test, P = 0.007). During the treatment, triglyceride showed an increasing trend, while the levels of total cholesterol, high-density lipoprotein, low-density lipoprotein, apolipoprotein A1 and apolipoprotein B decreased. Dyslipidemia and other indicators independently associated with HBsAg clearance were used to construct the nomogram model. The AUC of the model at 36-week and 48-week were 0.879 and 0.856, and the model demonstrated good discrimination and calibration.
CONCLUSION: Dyslipidemia can affect the antiviral efficacy of PegIFNα in NAs-experienced CHB patients. Our findings suggest that the nomogram model constructed using serum lipid has good predictive power and may help physicians to identify the superior patients for PegIFNα therapy.
Disclosed herein are systems and methods for providing interactive graphical user interfaces (GUIs) for users, such as medical professionals, to glean insight about connectivity data associated with a particular brain. A method can include overlaying nodes representing locations of parcels of a patient's brain on a representation of a brain and displaying the representation of the brain with the overlaid nodes in a GUI. Nodes having connectivity above a first threshold can be represented in a first indicia and nodes having connectivity below a second threshold can be represented in a second indicia. The method can include receiving user input and taking an action based on the user input. The user input can include selecting an area of the representation of the brain for excision. Taking an action based on the input can include calculating an impact of excising the area of the brain on the particular patient.
The invention provides raspberry fruit oil which is prepared with a method comprising the following steps: dried raspberry fruits are crushed and seeded; extraction is carried out through supercritical CO2 extraction; after extraction, two-level reduced-pressure separation is carried out, such that the raspberry fruit oil is obtained. The extraction conditions are that an extraction kettle pressure is 15-45Mpa, a temperature is 30-55 DEG C, a CO2 flow rate is 20-60L/h, and an extraction time is 40-120min. The two-level reduced-pressure separation conditions are that primary reduced-pressure separation is carried out under a pressure of 5-7Mpa and a temperature of 40-50 DEG C; and secondary reduced-pressure separation is carried out under a pressure of 3-5Mpa and a pressure of 30-40 DEG C. An obtained raspberry fruit oil soft capsule comprises, by mass, 55-75% of the raspberry fruit oil, 15-35% of gelatin, and 5-15% of glycerin. The invention also provides an application and the preparation method of the raspberry fruit oil. It is found in the invention that seeded raspberry fruit still contains oil components. The raspberry fruit oil obtained with the carbon dioxide supercritical extraction method has good anti-fatigue and anti-oxidation functions, and has good social and market values.
Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
Etodolac metabolites do not contribute significantly to the pharmacological activity of etodolac extended-release tablets.

Following administration of immediate-release etodolac, several metabolites have been identified in human plasma and urine. Other metabolites remain to be identified. The metabolites include 6-, 7-, and 8-hydroxylated etodolac and etodolac glucuronide. After a single dose of 14C-etodolac, hydroxylated metabolites accounted for less than 10% of total drug in serum. On chronic dosing, hydroxylated-etodolac metabolites do not accumulate in the plasma of patients with normal renal function. The extent of accumulation of hydroxylated-etodolac metabolites in patients with renal dysfunction has not been studied. The role, if any, of a specific cytochrome P450 system in the metabolism of etodolac is unknown. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces.